⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

モデル
薬剤
インサイト

Company

CROパートナー
Contact Us
Privacy Policy

© 2025 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Orforglipron (Orforglipron) | 加速させる、線維化研究を

Home/Drugs/Orforglipron

Orforglipron

Orforglipron

Phase 3

Sponsor: Eli Lilly

Indication: Obesity / MASH

Mechanism of Action

Oral GLP-1 Agonist

Target: GLP-1

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT05936138

A Study of LY3502970 in Participants With Normal and Impaired Renal Function

Phase:PHASE1Org:Eli Lilly and Company

COMPLETED

Relevant Publications (PubMed)

No recent publications found for Orforglipron.

Validated Models

This drug has been validated in the following preclinical models:

NCT05971940

A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

Phase:PHASE3Org:Eli Lilly and Company

RECRUITINGNCT06672549

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Phase:PHASE3Org:Eli Lilly and Company

ACTIVE_NOT_RECRUITINGNCT05803421

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Phase:PHASE3Org:Eli Lilly and Company

RECRUITINGNCT06672939

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

Phase:PHASE3Org:Eli Lilly and Company

View all trials on ClinicalTrials.gov